The Insulin Delivery Device Market To Grow With New Technologies
Being Brought To The Fore
The Insulin Delivery Device Market Share is slated to reach US$ 14.09
Billion between 2021 at a CAGR of 7%. The healthcare vertical, on the whole, is moving
towards value-based care. In other words, the trend towards consolidation asks for better
care at lower costs, with smaller hospitals showing affiliation with larger IDNs (Integrated
Delivery Networks). This would be a remarkable thing with regards to the healthcare
industry in the next decade.
Persistence Market Research Released New Market Report on “Global Market Study on
Insulin Delivery Devices – Asia to Witness Highest Growth by 2020” the global insulin
delivery devices market is estimated at USD 9,391.1 million in 2014 and is expected to grow
at a CAGR of 7% from 2014 to 2020, to reach an estimated value of USD 14,093.3 million in
The insulin delivery devices market is witnessing a significant growth due to the increasing
prevalence of diabetes and rising obese endemic. In addition, advanced features of insulin
delivery devices and rising awareness among people about diabetes care are also supporting
in the growth of the global insulin delivery devices market.
Get Going With Sample Of Insulin Delivery Device Market
Some of the major players operating in the market:
Novo Nordisk A/S.
Eli Lilly and Company.
Dickinson and Company.
F. Hoffmann-La Roche, Ltd.
How About Re-Inventing The Methodical Wheel In The Insulin Delivery Device Market?
Switch Over To The “Methodology”
However, risk and complications associated with the delivery of insulin and high cost of
insulin analog hampers the growth of global insulin delivery devices market. As a result, the
global insulin delivery devices market is expected to grow a CAGR of 7% during 2014-2020.